Patents Assigned to Jackson Laboratory
  • NON-HLA MATCHED HUMANIZED NSG MOUSE MODEL WITH PATIENT-DERIVED XENOGRAFT
    Publication number: 20220127638
    Abstract: The invention described herein provides non-HLA matched humanized mouse model (e.g., NSG mouse model) with patient-derived xenograft (PDX), as well as methods of making and using the same.
    Type: Application
    Filed: January 6, 2022
    Publication date: April 28, 2022
    Applicant: The Jackson Laboratory
    Inventor: James Keck
  • NON-HLA MATCHED HUMANIZED NSG MOUSE MODEL WITH PATIENT-DERIVED XENOGRAFT
    Publication number: 20220127639
    Abstract: The invention described herein provides non-HLA matched humanized mouse model (e.g., NSG mouse model) with patient-derived xenograft (PDX), as well as methods of making and using the same.
    Type: Application
    Filed: January 6, 2022
    Publication date: April 28, 2022
    Applicant: The Jackson Laboratory
    Inventor: James Keck
  • METHODS FOR PROMOTING WOUND HEALING AND HAIR GROWTH
    Publication number: 20220062381
    Abstract: The present invention generally relates to uses of glial cell line-derived growth factor (GDNF) in cutaneous wound healing and hair growth. Methods of effecting hair growth and/or wound healing which feature administration of GDNF, or a biologically active fragment thereof, to subjects, e.g., human subject, are disclosed herein. The invention relates also to formulations and kits for achieving the indicated pharmaceutical advantages.
    Type: Application
    Filed: July 13, 2021
    Publication date: March 3, 2022
    Applicant: The Jackson Laboratory
    Inventors: Robert E. Braun, Manju Sharma
  • METHOD AND APPARATUS FOR DETECTING COPY NUMBER VARIATIONS IN A GENOME
    Publication number: 20220059185
    Abstract: Techniques for detecting copy number variations (CNVs) in a genetic sequence, diagnosing disorders caused by CNVs, and treating disorders caused by CNVs are presented. The techniques include using a processor to perform steps of: scanning the genetic sequence to identify genetic regions corresponding to at least one autosomal chromosome, dividing the genetic sequence into bins, calculating a CNV status for each bin of the plurality of bins, and filtering the CNV statuses to identify at least one CNV in the genetic sequence.
    Type: Application
    Filed: September 13, 2019
    Publication date: February 24, 2022
    Applicant: The Jackson Laboratory
    Inventors: Wan-Ping Lee, Chengsheng Zhang, Qihui Zhu, Charles Lee
  • Non-HLA matched humanized NSG mouse model with patient-derived xenograft
    Patent number: 11248236
    Abstract: The invention described herein provides non-HLA matched humanized mouse model (e.g., NSG mouse model) with patient-derived xenograft (PDX), as well as methods of making and using the same.
    Type: Grant
    Filed: December 21, 2017
    Date of Patent: February 15, 2022
    Assignee: The Jackson Laboratory
    Inventor: James Keck
  • METHOD OF DETERMINING TOXICITY OF AN IMMUNOMODULATORY DRUG FOR USE IN HUMANS
    Publication number: 20220003781
    Abstract: Humanized mouse models and methods are provided for determining whether administration of an immunomodulatory drug likely elicits a severe cytokine release syndrome in a human. Humanized mouse models and methods are also provided for determining the immunotoxicity in a human of a drug candidate or of drug combinations.
    Type: Application
    Filed: April 17, 2018
    Publication date: January 6, 2022
    Applicant: The Jackson Laboratory
    Inventors: James Keck, Chunting Ye
  • TREATMENTS FOR CHARCOT-MARIE-TOOTH DISEASE
    Publication number: 20210393591
    Abstract: Provided herein, in some embodiments, are methods and compositions for the treatment of Charcot-Marie-Tooth disease, comprising an inhibitor of a GCN2 pathway component.
    Type: Application
    Filed: October 25, 2019
    Publication date: December 23, 2021
    Applicant: The Jackson Laboratory
    Inventors: Robert W. Burgess, Emil Spaulding
  • ARTIFICIAL RNA-GUIDED SPLICING FACTORS
    Publication number: 20210388351
    Abstract: Provided herein, in some aspects, are compositions and methods for artificially modulating alternative splicing, for example, inducing exon inclusion and/or exon exclusion events. In some embodiments, a catalytically inactive programmable nuclease, such as dCasRx, is fused to an RNA-binding protein (or fragment or isoform thereof) and, when guided to a target of interest by a specific guide RNA (gRNA), can regulate alternative splicing in eukaryotic cells.
    Type: Application
    Filed: September 27, 2019
    Publication date: December 16, 2021
    Applicant: The Jackson Laboratory
    Inventors: Albert Cheng, Nathaniel Jillette
  • METHODS AND APPARATUS FOR PHENOTYPE-DRIVEN CLINICAL GENOMICS USING A LIKELIHOOD RATIO PARADIGM
    Publication number: 20210343414
    Abstract: Methods and apparatus for providing clinical decision support. The method comprises receiving phenotype information for a patient, determining a likelihood ratio for each of the phenotype features included in the received phenotype information with respect to each of a plurality of diseases, determining, based on the likelihood ratio for each of the phenotype features, a composite likelihood ratio for each of the plurality of diseases, ranking the plurality of diseases based, at least in part, on the determined composite likelihood ratios, and displaying at least some of the ranked plurality of diseases.
    Type: Application
    Filed: October 21, 2019
    Publication date: November 4, 2021
    Applicant: The Jackson Laboratory
    Inventor: Peter N. Robinson
  • GASTRIC CANCER TREATMENTS
    Publication number: 20210322417
    Abstract: Provided herein, in some embodiments, are methods, compositions, and kits for treating lapatinib-resistant gastric cancer.
    Type: Application
    Filed: April 30, 2021
    Publication date: October 21, 2021
    Applicant: The Jackson Laboratory
    Inventors: Chengsheng Zhang, Charles Lee, Gang Ning, Yun-Suhk Suh, Qihui Zhu
  • DLGAP2 AS A THERAPEUTIC TARGET FOR AND ALZHEIMER'S DISEASE AND AGE-RELATED COGNITIVE DECLINE
    Publication number: 20210321594
    Abstract: Provided herein, in some embodiments, are methods for modulating expression and/or activity of disks large-associated protein 2 (DLGAP2), as well as methods of treating age-related cognitive decline, such as Alzheimer's disease.
    Type: Application
    Filed: April 30, 2021
    Publication date: October 21, 2021
    Applicant: The Jackson Laboratory
    Inventors: Catherine Kaczorowski, Sarah M. Neuner
  • METHODS FOR PREVENTING AND TREATING TYPE II DIABETES
    Publication number: 20210317473
    Abstract: Provided herein, in some aspects, are methods for preventing or treating diabetes in a subject, the method comprising assaying a genomic sample obtained from the subject for an intergenic variant located in a region between a C2 calcium-dependent domain containing 4A gene (C2CD4A) and a C2 calcium-dependent domain containing 4B gene (C2CD4B), and when the intergenic variant is present in the genomic sample, administering to the subject a therapy for diabetes. Also provided herein are rodent cells homozygous for a C2cd4a mutation and/or homozygous for a C2cd4h mutation, and methods for producing the rodent cells.
    Type: Application
    Filed: January 31, 2019
    Publication date: October 14, 2021
    Applicant: The Jackson Laboratory
    Inventor: Michael Stitzel
  • THREE DIMENSIONAL HUMAN BRAIN TUMOR MODELS
    Publication number: 20210317417
    Abstract: Provided herein, in some embodiments, are human patient-derived brain tumor models and methods of use.
    Type: Application
    Filed: April 27, 2021
    Publication date: October 14, 2021
    Applicant: The Jackson Laboratory
    Inventor: Min Tang-Schomer
  • BREAST CANCER SPLICE VARIANTS
    Publication number: 20210254176
    Abstract: Provided herein, in some embodiments, are methods, compositions, and systems for identifying alternatively spliced tumor-specific exon inclusion and exclusion events that can be used for survival prognosis.
    Type: Application
    Filed: June 28, 2019
    Publication date: August 19, 2021
    Applicant: The Jackson Laboratory
    Inventors: Jacques Banchereau, Diogo Fernando Troggian Veiga, Anne Deslattes Mays, Saman Zeeshan, Anna Karolina Palucka
  • METHODS AND APPARATUS FOR IDENTIFYING ALTERNATIVE SPLICING EVENTS
    Publication number: 20210233640
    Abstract: Methods and apparatus for identifying alternative splicing events. The method comprises receiving a dataset of percent spliced in (PSI) values for each of a plurality of biological samples, wherein the plurality of biological samples includes a first population of samples having a first characteristic and a second population of samples having a second characteristic different from the first characteristic, fitting, to the dataset, a probabilistic model to identify clusters of samples in the dataset, calculating cluster characteristics for each of the clusters, filtering the clusters based, at least in part, on the cluster characteristics to identify a subset of clusters, each of which is associated with an alternative splicing event, and storing on the at least one storage device, information associated with the identified alternative splicing events.
    Type: Application
    Filed: June 26, 2019
    Publication date: July 29, 2021
    Applicant: The Jackson Laboratory
    Inventors: Jacques Banchereau, Diogo Fernando Troggian Veiga, Anne Deslattes Mays
  • Methods for multiplex chromatin interaction analysis by droplet sequencing with single molecule precision
    Patent number: 11074991
    Abstract: The invention, in part, relates to ChIA-Drop methods, which comprise methods of drop-based sequencing.
    Type: Grant
    Filed: December 27, 2018
    Date of Patent: July 27, 2021
    Assignee: The Jackson Laboratory
    Inventors: Meizhen Zheng, Yijun Ruan, Chia-Lin Wei, Zhongyuan Tian
  • GENETICALLY MODIFIED MOUSE MODELS OF ALZHEIMER'S DISEASE
    Publication number: 20210195879
    Abstract: The present disclosure provides a genetically modified mouse comprising a genomic nucleic acid encoding human APOE4, a genomic nucleic acid encoding mouse TREM2 modified to include a R47H substitution, and at least one genomic modification selected from the group consisting of: (a) a genomic nucleic acid encoding mouse ABCA7 modified to include an A 1541 G substitution; (b) a genomic nucleic acid encoding mouse APP modified to include G601R, F606Y, and R609H substitutions; (c) a genomic nucleic acid encoding mouse PLCG2 modified to include a M28L substitution; (d) a genomic nucleic acid encoding mouse MTHFR modified to include a A262V substitution; (e) an inactivated Ceacam1 allele; and (f) an inactivated Il1rap allele. Methods of producing the genetically modified mouse and methods of using the genetically modified mouse are also provided.
    Type: Application
    Filed: June 21, 2019
    Publication date: July 1, 2021
    Applicants: The Jackson Laboratory, Indiana University Research and Technology Corporation, Sage Bionetworks
    Inventors: Gareth Howell, Gregory Carter, Michael Sasner, Stacey Rizzo, Harriet Williams, Bruce Lamb, Paul Territo, Adrian Oblak, Ben Logsdon, Lara Mangravite, Leah Graham
  • SEQUENCE DETECTION SYSTEMS
    Publication number: 20210189485
    Abstract: The present disclosure, in some embodiments, provides sequence detection systems (sequence detectors) for the detection of specific nucleotides sequences present in the genome of live cells (e.g., single live cells) to achieve, for example, in vivo and in situ imaging, cell selection, and/or cell ablation.
    Type: Application
    Filed: November 6, 2018
    Publication date: June 24, 2021
    Applicant: The Jackson Laboratory
    Inventors: Albert Cheng, Aziz Taghbalout, Nathaniel Lee Jillette
  • ANTI-NGLY-1 ANTIBODIES AND METHODS OF USE
    Publication number: 20210139607
    Abstract: Provided herein, in some embodiments, are anti-N-gly-canase 1 antibodies and methods of use.
    Type: Application
    Filed: May 22, 2019
    Publication date: May 13, 2021
    Applicant: The Jackson Laboratory
    Inventors: Alan Sawyer, Aamir Zuberi, Cathleen Marie Lutz
  • METHOD OF DETERMINING TOXICITY OF AN IMMUNOMODULATORY DRUG FOR USE IN HUMANS
    Publication number: 20210132080
    Abstract: Humanized mouse models and methods are provided for determining whether administration of an immunomodulatory drug likely elicits a severe cytokine release syndrome in a human. Humanized mouse models and methods are also provided for determining the immunotoxicity in a human of a drug candidate or of drug combinations.
    Type: Application
    Filed: April 17, 2018
    Publication date: May 6, 2021
    Applicant: The Jackson Laboratory
    Inventors: James Keck, Chunting Ye